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ABSTRACT: Chemical generation of singlet oxygen under
biologically relevant conditions is very important, considering
the role played by singlet oxygen in cancer therapeutics. We
now demonstrate that a luminol derivative can be chemically
excited and transfer the excitation energy to the covalently
attached photosensitizer derived from erythrosin. A photo-
sensitizer module, when excited in this manner, can generate
singlet oxygen in solution. As hydrogen peroxide is present in a
relatively high concentration in cancer cells, singlet oxygen
generation through chemical excitation may evolve into an
important therapeutic approach.
■ INTRODUCTION
Singlet oxygen is the primary cytotoxic agent involved in
photodynamic therapy (PDT) of cancer.1 Generation of singlet
oxygen requires a photosensitizer, dissolved molecular oxygen,
and light of an appropriate wavelength for excitation of the
photosensitizer.2 An excited photosensitizer should be capable
of undergoing efficient intersystem crossing3 so that energy
transfer to the ground-state molecular oxygen can take place.
The fact that light is needed for the generation of singlet
oxygen is both an advantage (increased spatial selectivity) and a
disadvantage (light does not penetrate tissues to more than a
few millimeters). Attenuation of light as it passes through
tissues is one of the factors limiting the clinical practice of PDT
to mostly superficial lesions.4 Despite considerable efforts to
alleviate these problems with new light sources, photo-
sensitizers, and novel delivery methods, they seem to remain
as intractable as ever.5
There are proposed alternatives to in vivo irradiative
generation of singlet oxygen, such as X-ray-induced scintillating
nanoparticles6 or persistent luminescent nanoparticles. The
former approach attempts to excite using penetrating
radiation,7 whereas the latter separates the excitation step
from the singlet oxygen generation step. Recently, we also
introduced the use of endoperoxide for the potential bypass of
excitation altogether.8
In this work, our aim was to couple chemical excitation with
singlet oxygen generation in a modular unimolecular system.
The use of chemiluminescence or bioluminescence as a source
of excitation for photosensitizers has been investigated
previously.9 Unfortunately, the conditions for efficient (non-
radiative) energy transfer required the use of a chemiluminesc-
ing agent and photosensitizer in large concentrations, limiting
the potential of this approach at conception. However, a
through-bond energy transfer to a photosensitizer would
circumvent the problem caused by two independent agents
by directly generating singlet oxygen upon chemical excitation.
The synthesis of the target compound, 11, was done in multiple
steps from commercially available products (Scheme 1).
Compound 10 has been previously reported10 as an energy-
transfer cassette. The final step was halogenation of the
xanthene nucleus to introduce heavy iodine atoms to facilitate
intersystem crossing. As expected, iodination resulted in
significant quenching of the fluorescence as it allows rapid
access to the triplet manifold.
■ RESULTS AND DISCUSSION
The general design principle is shown in Figure 1. The idea is
to bring the chemiluminegenic unit in close proximity to the
photosensitizer, thus ensuring a highly effective concentration.
The chemiluminescence energy is likely to be efficiently
transferred by through-bond energy transfer, but considering
the short distance that the chemiluminogen can be placed at in
relation to the photosensitizer, a through-space energy transfer
can be envisioned. On triggering of the chemiluminescence
reaction, the resulting excited-state species would be expected
to transfer their energy to the photosensitizer, which in turn
would sensitize singlet oxygen. Hydrogen peroxide is
particularly relevant and important as a trigger compound for
two reasons: (i) it is known to be present in high
concentrations in tumor cells,11 in fact high enough to trigger
chemiluminescence and12 (ii) there are several different
chemiluminogen systems (oxalates, acridinium esters, etc.)
that can be activated by hydrogen peroxide.
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The absorption spectrum of compound 11 (Figure 2) shows
one peak in the visible region at 530 nm. Introduction of four
iodo substituents causes a redshift in absorbance compared to
that of a typical unsubstituted xanthene dye.
We first wanted to demonstrate that a tetraiodoxanthene
(erythrosin)-derived module is satisfactory as a photosensitizer.
To that end, a solution of the erythrosin−luminol conjugate
was prepared in a DMSO-containing singlet oxygen trap,
DPBF. When kept in the dark for 8 min, there was no
discernable change in the absorption spectrum (Figure 3).
However, on irradiation with a green LED (520 nm, fluence
rate 2.5 mW/cm2), the absorption peak due to the trap
compound, DPBF, rapidly disappeared in 14 min. This
indicates that the photosensitizer module, which is structurally
related to erythrosin, retains a high level of photosensitization
capacity within the bifunctional construct.
The chemical generation of singlet oxygen was then studied
in DMSO solution (Figure 3) with a small amount of added
aqueous buffer solution. Careful control experiments were
performed to eliminate other potential sources of decrease in
absorbance. The absorption of the singlet oxygen trap (DPBF,
black squares) was followed in the presence of carbonate buffer
(10% buffer, 90% DMSO volume percentage), catalytic Cu2+,
and hydrogen peroxide (final concentration 0.20 mM).
Compound 10 was also investigated under same conditions
and showed no change (red circles). However, compound 11,
added to the reaction mixture at t = 8.0 min, resulted in a rapid
decrease, leveling off, as expected, within 12 min. This is also in
accordance with the typical chemiluminescence kinetics of
luminol under comparable conditions. Naturally, due to the
solubility restrictions, the chemical excitation was tested under
Scheme 1. Synthesis of Compound 11 from Commercially Available and/or Easily Accessible Compoundsa
aThe key intermediate, 10, was synthesized essentially following a previously published procedure.10
Figure 1. General principle for singlet oxygen generation via chemical
excitation. Hydrogen peroxide would be a preferred initiator. CL:
chemiluminogen module, PS: photosensitizer module, PS*: excited
photosensitizer.
Figure 2. Reaction of the singlet oxygen generated by photo-
sensitization with 47 μM 1,3-diphenyl-isobenzofuran (DPBF) in
dimethyl sulfoxide (DMSO) in the presence of erythrosine−luminol
conjugate 11. For the first 8 min, the solution was kept in the dark;
thereafter, it was irradiated with a 520 nm light-emitting diode (LED)
array for 16 min. The total volume was adjusted to 3.0 mL.
Absorbance spectra were recorded in 2 min intervals.
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highly suboptimal conditions. However, we estimated the
chemical yield of singlet oxygen on the basis of the
concentration of compound 11 and the decrease in the
absorption of DPBF as 4.2%, which is promising considering
the chemical and photophysical processes involved in singlet
oxygen generation. The yield is most likely held restricted by
the solubility of molecular oxygen.
■ CONCLUSIONS
Our previous work8b demonstrated that a small amount of
singlet oxygen generated within tumors may be sufficient to
induce apoptosis. We are confident that with appropriate
modifications to improve water solubility coupling singlet
oxygen generation with hydrogen peroxide levels will evolve
into a promising methodology for tumor therapy. Work in that
direction is in progress in our laboratory.
■ EXPERIMENTAL SECTION
1H NMR and 13C NMR spectra were recorded on a Bruker
DPX-400 spectrometer (operating at 400 MHz for 1H NMR
and 100 MHz for 13C NMR). Chemical shifts are reported in
units of parts per million relative to those of the solvent peak
(CDCl3: 7.27 ppm for
1H and 77.0 ppm for 13C; D2O: 4.63
ppm for 1H). All spectra were recorded at 25 °C, and the
coupling constants (J values) are given in hertz. Chemical shifts
are given in parts per million. Absorption spectra were recorded
using a Varian Cary-100 spectrophotometer. Fluorescence
measurements were conducted on a Varian Eclipse spectro-
fluorometer. Mass spectra were recorded on an Agilent
Technologies 6530 Accurate-Mass Q-TOF LC/MS system.
Reactions were monitored by thin-layer chromatography using
Merck TLC Silica gel 60 F254. Silica gel column chromatog-
raphy was performed over Merck Silica gel 60 (particle size:
0.040−0.063 mm, 230−400 mesh ASTM). Anhydrous
tetrahydrofuran was obtained by refluxing over sodium/
benzophenone prior to use. All other reagents and solvents
were purchased from Aldrich and used without further
purification. DPBF was used as the singlet oxygen trap.
Compound 3. 6-Bromo-2,3-dihydrophthalazine-1,4-dione
(0.300 g, 1.24 mmol) was dissolved in 8.5 mL of dry DMF and
cooled to 0 °C. NaH (104.0 mg, 2.6 mmol) was added, and the
reaction mixture was stirred for 45 min; then, 4-methoxybenzyl
chloride (0.36 mL, 2.6 mmol) was added dropwise. The
reaction mixture was stirred at room temperature overnight,
extracted with EtOAc (3 × 10 mL), and then washed with
water (3 × 10 mL). The organic layer was dried with Na2SO4
and evaporated under reduced pressure. The product was
purified by silica gel column chromatography using ethyl
acetate/hexane (10:90, v/v) as the mobile phase. The fraction
containing compound 3 was collected, and then the solvent was
removed under reduced pressure (180 mg, 30%). 1H NMR
(400 MHz, CDCl3) δ 8.55 (s, 1H), 7.81 (s, 2H), 7.43 (d, J =
8.6 Hz, 2H), 7.36 (d, J = 8.6 Hz, 2H), 6.92 (d, J = 8.6 Hz, 2H),
6.87 (d, J = 8.6 Hz, 2H), 5.29 (s, 2H), 5.24 (s, 2H), 3.84 (s,
3H), 3.80 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 159.7,
159.2, 157.1, 149.2, 135.9, 130.6, 130.3, 130.1, 130.1, 129.2,
128.3, 126.7, 125.3, 123.4, 114.0, 113.9, 68.6, 55.3, 53.6. MS
(TOF-ESI): m/z: calcd: 481.0757 [M + H]+, found: 481.0628
[M + H]+, Δ = 26.9 ppm.
Compound 6. In a round-bottom flask (100.0 mL), 4-
bromophthalic anhydride (8.75 g, 38.6 mmol) and resorcinol
(8.50 g, 77.3 mmol ) were heated for 12 h. A dark brown solid
was formed. After cooling, 60 mL of acetic anhydride was
added, and then, the mixture was refluxed for 3 h. The reaction
mixture was cooled to room temperature slowly for
recrystallization. Brownish crystals were collected and washed
with cold acetic anhydride and then with cold ethanol.
Recrystallization was repeated several times until white crystals
were obtained. 1H NMR (400 MHz, CDCl3) δ 8.18 (dd, J =
1.7, 0.4 Hz, 1H), 7.82 (dd, J = 8.2, 1.8 Hz, 1H), 7.14−7.11 (m,
2H), 7.10 (dd, J = 8.3, 0.4 Hz, 1H), 6.85 (s, 4H), 2.34 (s, 6H).
13C NMR (100 MHz, CDCl3) δ 168.9, 167.5, 152.1, 151.5,
151.3, 138.4, 128.7, 128.1, 125.6, 124.2, 117.9, 115.7, 110.5,
81.8, 20.9. MS (TOF-ESI): m/z: calcd: 519.005 [M + Na]+,
found: 518.9966 [M + Na]+, Δ = 16.2 ppm.
Compound 7. 5-Bromofluorescein diacetate 6 (250 mg, 0.5
mmol), CuI (4.8 mg, 0.025 mmol), and palladium-
(tetrakistriphenylphosphine) (17.5 mg, 0.025 mmol) were
added to 0.5 mL of dry tetrahydrofuran (THF) in a Schlenk
flask under an argon atmosphere. Thereafter, NEt3 (0.7 mL, 5
mmol) was added followed by trimethylsillyl acetylene (0.14
mL, 1 mmol) and the reaction mixture was heated to 72 °C for
6 h. The mixture was concentrated in vacuo and then purified
by flash chromatography (25% EtOAc/hexane). Pale yellow
crystals were formed (yield: 170 mg, 66%). 1H NMR (400
MHz, CDCl3) δ 8.11 (s, 1H), 7.75 (dd, J = 8.0, 1.4 Hz, 1H),
7.14 (d, J = 8.0 Hz, 1H), 7.12−7.10 (m, 2H), 6.85−6.81 (m,
4H), 2.32 (s, 6H), 0.30 (s, 9H). 13C NMR (100 MHz, CDCl3)
δ 169.0, 168.0, 152.0, 151.4, 138.7, 128.8, 128.4, 126.5, 125.6,
124.0, 117.8, 116.2, 110.3, 102.6, 97.5, 81.8, 20.9, 0.01. MS
(TOF-ESI): m/z: calcd: 514.1448 [M + 2H]+, found: 514.1418
[M], Δ = 5.8 ppm.
Compound 8. 5-(2-Trimethylsilylethynyl)fluorescein diac-
etate 7 (200 mg, 0.389 mmol) was dissolved in 6 mL of dry
THF. Then, tetra-n-butylammonium fluoride (0.39 mL, 1.0 M
in THF) was added, and the mixture was concentrated in
vacuo. The crude orange solid obtained was purified by flash
chromatography (25% EtOAc/hexane). 1H NMR (400 MHz,
CDCl3) δ 8.14 (s, 1H), 7.78 (dd, J = 7.9 Hz, 1.4 Hz, 1H), 7.17
(d, J = 7.9 Hz, 1H), 7.14−7.11 (m, 2H), 6.87−6.83 (m, 4H),
3.25 (s, 1H), 2.33 (s, 6H). 13C NMR (100 MHz, CDCl3) δ
Figure 3. Change in the absorbance of 47.0 μM DPBF in DMSO in
the presence of 104.0 μM of compound 10 or 11. The sample
solutions contain 300 μL of pH 10.0 buffer solution (Na2CO3 and
NaHCO3). After 8 min, chemical excitation is induced by 300 μL of
1.5 × 10−3 M CuSO4 and 2 × 10
−3 M H2O2. The total volume was
adjusted to 3.0 mL. Absorbance data were recorded in 2 min intervals.
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168.8, 168.1, 152.6, 152.2, 151.6, 138.8, 128.8, 128.7, 126.5,
124.6, 124.2, 117.8, 115.9, 110.5, 81.7, 81.5, 79.8, 21.3. MS
(TOF-ESI): m/z: calcd: 465.0945 [M + Na]+, found: 465.0856
[M + Na]+, Δ = 19.1 ppm.
Compound 9. Compound 3 (335 mg, 0.699 mmol) and
compound 6 (335 mg, 0.769 mmol), bis(triphenylphosphine)
palladium chloride (26.0 mg, 0.065 mmol), copper(I) iodide
(13 mg, 0.13 mmol), NEt3 (0.98 mL, 6.99 mmol), and 8.0 mL
of dry THF were added into a microwave tube. The reaction
mixture was microwave-irradiated at 120 °C for about 25 min.
The solvent was removed under reduced pressure, and the
product was purified by silica gel column chromatography using
ethyl acetate/hexane (25:75, v/v) as the mobile phase. White
crystals were formed (262 mg, 45%). 1H NMR (400 MHz,
CDCl3) δ 8.58 (s, 1H), 8.19 (s, 1H), 7.96 (d, J = 8.3 Hz, 1H),
7.90−7.84 (m, 2H), 7.45 (d, J = 8.5 Hz, 2H), 7.40 (d, J = 8.5
Hz, 2H), 7.22 (d, J = 8.0 Hz, 1H), 7.12 (s, 2H), 6.98−6.82 (m,
8H), 5.30 (s, 2H), 5.26 (s, 2H), 3.83 (s, 3H), 3.79 (s, 3H), 2.33
(s, 6H). 13C NMR (100 MHz, CDCl3) δ 168.8, 168.1, 159.6,
159.2, 157.6, 152.6, 152.2, 151.5, 149.2, 138.4, 135.2, 130.6,
130.3, 130.1, 129.3, 129.2, 128.9, 128.3, 126.6, 126.0, 125.0,
124.3, 124.2, 123.8, 117.9, 115.9, 113.9, 113.8, 110.5, 90.4,
81.83, 68.5, 55.2, 53.5, 21.1. MS (TOF-ESI): m/z: calcd:
842.2476 [M]+, found: 842.2399 [M]+, Δ = 9.1 ppm.
Compound 10. Compound 9 (80.0 mg, 0.01 mmol) and
8.0 mL of TFA were mixed and heated to 70 °C for 1 h. The
mixture was concentrated in vacuo. The reaction product was
dissolved in 2.0 mL of 1.0 M NaOH. Then, two drops of HCl
were added, and a yellow-orange solid precipitated. The
precipitate was filtrated and washed with water and EtOAc. A
yellow solid was afforded (36 mg, 75%). 1H NMR (400 MHz,
D2O) δ 7.88 (s, 1H), 7.83 (s, 1H), 7.79 (d, J = 8.2 Hz, 1H),
7.58 (d, J = 7.8 Hz, 1H), 7.47 (d, J = 8.2 Hz, 1H), 7.24 (d, J =
7.8 Hz, 1H), 7.01 (d, J = 9.3 Hz, 2H), 6.47 (d, J = 9.3 Hz, 2H),
6.33 (s, 2H). MS (TOF-ESI): m/z: calcd: 517.103 [M + H]+,
found: 517.0966 [M + H]+, Δ = 12.4 ppm.
Compound 11. Compound 10 (16.0 mg, 0.03 mmol), 0.5
mL of saturated sodium bicarbonate solution, 0.5 mL of 0.1 M
NaI solution, and 31.4 mg of iodine were mixed and refluxed
for about 40 min. The mixture was cooled to room temperature
and 0.4 mL of H2SO4 was added and extracted with EtOAc.
The aqueous layer was separated, and the organic layer was
washed with water two times. Finally, the organic layer was
washed with 10% sodium thiosulfate solution. A faint red solid
was afforded (5.0 mg, 15%). 1H NMR (400 MHz, MeOD) δ
8.41 (s, 1H), 8.32−8.16 (m, 2H), 7.96 (d, J = 8.2 Hz, 1H), 7.78
(d, J = 8.0 Hz, 1H), 7.30 (d, J = 7.9 Hz, 1H), 7.09 (d, J = 9.3
Hz, 2H), 6.68−6.39 (m, 4H). MS (TOF-ESI): m/z: calcd for
C30H13I3N2O7: 893.78568 [M − I − H]+, found: 893.74085
[M], Δ = 50.2 ppm.
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